Please Read Our Disclaimer
Biopep Solutions Inc.
Sector: Life Science
Biopep Solutions Inc. is a privately owned, late-preclinical stage biotechnology company whose general mission is to discover and develop innovative therapeutic products for the treatment of cancers and other diseases.
Need for a drug that is not susceptible to drug resistance –The overwhelming majority of anticancer drugs on the market today are susceptible to resistance and become less effective or ineffective over time.
Need for a cancer therapy with minimal side effects – Cancer therapies are known to be some of the more toxic therapies available. As well as being toxic, they are often non-specific meaning that they do not only target cancerous tissue, healthy tissue is also effected.
Need for effective late stage prostate cancer therapy – If caught early, prostate cancer is often treatable. However late-stage prostate cancer patients have fewer effective treatment options.
Cancer is a very aggressive indication that finds alternative pathways to multiply. Current therapies target singular pathways that. Consequently a patient must enlist multiple therapies to conquer the aggressive nature of a cancer – Cancer’s multivalent mechanism is the processes by which cancer cells use more than one channel to grow and spread. BPS-001’s multivalent mechanism responds to this occurrence by targeting these channels.
Their lead drug candidate, BPS-001, is a unique disruptive therapy for various forms of cancer. The initial target indication is prostate cancer. Unlike conventional therapies like chemotherapy, hormone depravation therapy or immunotherapy, BPS-001 has the following advantages.
- A multivalent mechanism, which targets multiple pathways and sites on the cancer cell, which means the cancer will be unable to develop resistance to the treatment which is the case in current
- Inhibits angiogenesis (the formation of new blood vessels from existing blood vessels).
- Increases apoptosis (a process of programmed cell death) of cancer cells.
- Exhibits properties that counter inflammation.
- BPS-001 has very low toxicity giving it a large therapeutic
- Ease of administration, a once weekly subcutaneous
Ahmed Merzouk, Director, President and Chief Executive Officer
Dr. Merzouk has more than 20 years’ experience in industry and academia in drug discovery of small and large molecules. The expertise of Dr. Merzouk ranges from design, synthesis, and purification of synthetic molecules to extraction of active ingredients from natural sources.
Yalcin Ilsever, PhD, CPA.CGA, IMA(USA),FICB, Director, Executive Vice President and Chief Financial Officer
Dr. Ilsever is a Chartered Professional Accountant (CPA). His PhD is in Accounting, Finance and Statistical Measurement. He has extensive experience in the private sector in the issuance of fixed income securities and equities. Dr. Ilsever has also published extensively on electronic commerce platforms, and business measurement systems.
Gary Yalloway, PhD, Director, Vice President, Regulatory Affairs and Drug Development
Dr. Yalloway has over 22 years of multidisciplinary experience in industry and academia and skills in enzyme engineering and protein purification of proteins of medical and industrial interest. He has significant experience in regulatory affairs with both the US Food and Drug Administration and Health Canada. He is highly experienced in all aspects of R&D, process development, and the scale-up and manufacture of therapeutic proteins. His specialties include upstream and downstream processing, including large-scale production and bulk manufacturing of recombinant proteins.